Search results
Results from the WOW.Com Content Network
In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma. [30] In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118.
Deadline: The application is open from December 1st to February 1st each year. ... UNCF Healthcare Workforce Diversity Program. Sponsored by the AbbVie Foundation, the UNCF Healthcare Workforce ...
A federal grant is an award of financial assistance from a federal agency to a recipient to carry out a public purpose of support or stimulation authorized by a law of the United States. Grants are federal assistance to individuals, benefits or entitlements. A grant is not used to acquire property or services for the federal government's direct ...
The Entrepreneur-in-Residence program is a free service provided by Research Park which consists of 7 experience tech entrepreneurs who provide monthly consulting to new startup ventures and prospective entrepreneurs. [4]
Spectrum Pharmaceuticals, Inc. is an American biopharmaceutical company located in Boston, MA.It develops and markets drugs for treatments in hematology and oncology.. After a deal valued at $248 million was announced in April 2023, [1] [2] Assertio Holdings announced that it had completed its acquisition of the Massachusetts-based company on July 31.
Research funding is a term generally covering any funding for scientific research, in the areas of natural science, technology, and social science.Different methods can be used to disburse funding, but the term often connotes funding obtained through a competitive process, in which potential research projects are evaluated and only the most promising receive funding.
In March 2015, Chicago-based biopharmaceutical firm AbbVie announced it would acquire Pharmacyclics, as well as its lead anti-cancer compound ibrutinib (Imbruvica) for $21 billion. As part of the deal, AbbVie will pay $261.25 per share in a mixture of both cash and AbbVie equity. [6] The merger is expected to close in mid-2015. [7]
BioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999. [7] Seed investors were amongst others MPM Bioventures, Grosvenor Fund and Florian Schönharting. [8]